


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31199473</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1945-7170</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Endocrinology</Title>
                <ISOAbbreviation>Endocrinology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Role of hepatic glucocorticoid receptor in metabolism in models of 5αR1 Deficiency in Male Mice.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">en.2019-00236</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1210/en.2019-00236</ELocationID>
            <Abstract>
                <AbstractText>Inhibition of 5α-reductases impairs androgen and glucocorticoid metabolism and induces insulin resistance in humans and rodents. The contribution of hepatic glucocorticoids to these adverse metabolic changes was assessed utilizing a liver-selective glucocorticoid receptor (GR) antagonist, A-348441. Mice lacking 5α-reductase 1 (5αR1-KO) and their littermate controls were studied on a high fat diet, with or without A-348441(120 mg.kg-1.day-1). Male mice C57BL/6 (12 weeks) were also studied receiving dutasteride (1.8 mg.kg-1.day-1or vehicle) within a high fat diet, with or without A-348441. In 5αR1-KO mice, hepatic GR antagonism improved diet-induced insulin resistance, but not more than controls. Liver steatosis was not affected by hepatic GR antagonism in either 5αR1-KO mice nor their littermate controls. In a second model of 5α-reductase inhibition using dutasteride, hepatic GR antagonism with A-348441 attenuated excess weight gain brought about by dutasteride administration (7.03±0.5vs.2.13±0.4g; dutasteride vs. dutasteride+A-348441; mean±SEM, p&lt;0.05) and normalized the associated hyperinsulinemia after glucose challenge (AUC: 235.9±17vs.329.3±16vs.198.4±25*ng.mL-1min-1; high fat, high fat+dutasteride, high fat+dutasteride+A-348441, respectively; *p&lt;0.05). However, A-348441 again did not reverse dutasteride-induced liver steatosis. Thus, overall hepatic GR antagonism improves insulin resistance but not steatosis induced by high fat diet. Moreover, it attenuates excessive insulin resistance caused by pharmacological inhibition of 5α-reductases, but not genetic disruption of 5αR1. Dutasteride might put patients at increased risk of type 2 diabetes mellitus and reduced exposure to glucocorticoids may be beneficial.</AbstractText>
                <CopyrightInformation>Copyright © 2019 Endocrine Society.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mak</LastName>
                    <ForeName>Tracy Cs</ForeName>
                    <Initials>TC</Initials>
                    <AffiliationInfo>
                        <Affiliation>University/British Heart Foundation Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Little France Crescent, Edinburgh, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Livingstone</LastName>
                    <ForeName>Dawn Ew</ForeName>
                    <Initials>DE</Initials>
                    <AffiliationInfo>
                        <Affiliation>University/British Heart Foundation Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Little France Crescent, Edinburgh, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nixon</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>University/British Heart Foundation Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Little France Crescent, Edinburgh, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Walker</LastName>
                    <ForeName>Brian R</ForeName>
                    <Initials>BR</Initials>
                    <AffiliationInfo>
                        <Affiliation>University/British Heart Foundation Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Little France Crescent, Edinburgh, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Andrew</LastName>
                    <ForeName>Ruth</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>University/British Heart Foundation Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Little France Crescent, Edinburgh, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Endocrinology</MedlineTA>
            <NlmUniqueID>0375040</NlmUniqueID>
            <ISSNLinking>0013-7227</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31199473</ArticleId>
            <ArticleId IdType="pii">5518336</ArticleId>
            <ArticleId IdType="doi">10.1210/en.2019-00236</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

